100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Neuropharmacology notes for exam 2 and 3 $10.49   Add to cart

Class notes

Neuropharmacology notes for exam 2 and 3

 3 views  0 purchase
  • Course
  • Institution

These 2 documents contain information about exam 2 and 3 in that course, Neurodevelopmental disorders and Neurodegeneration disorders, namely: Epilepsy, mechanisms for pain & addiction, Alzheimer's disease, Parkinson's disease, ALS, FTD and SMA.

Preview 3 out of 30  pages

  • December 15, 2023
  • 30
  • 2023/2024
  • Class notes
  • Bowie
  • Materials for exam 2 and exam 3
avatar-seller
PHAR 562


Neurodegeneration – Motor neuron disease
Vocab

Motor neuron disease
- Impairment in muscle innervation
Spinal Muscular Atrophy
- Early impairment of muscle innervation
Ataxia
- Loss of voluntary movement
Dementia
- Memory and cognitive functions impairment
o AD
o Vascular Dementia
o PD
o HD
o Lewy body dementia
o Trisomy 21
Multiple sclerosis
- Degeneration of myelin sheaths

Anatomy
- Motor unit => basic unit of motor function
o A motor neuron and the group of muscle fibers it innervates
- Upper and lower motor neurons
o Upper
 Derive from motor cortex / brain stem
 Project to lower motor neurons
 Release glutamate on the lower motor neurons as means of
communication
o Lower
 Located in spinal cord
 Innervate muscles and mediates voluntary movement
 Exception cranial nerve is the lower motor neuron with nuclei
located in brainstem as it innervates tongue and eyes
- Motor Neuron Diseases
o Occur when motor neurons become damaged
o Present as muscle weakness
 Muscles are less innervated => loss of control
 May lead to difficulty breathing & swallowing
o UMN diseases may present differently from LMN diseases
 Amyotrophic lateral sclerosis (ALS)
 UMN and LMN are both affected

,PHAR 562


 Most common motor neuron disease
 Dysmorphic disease – weakness that spreads
 Diverse pathology
 Primary Lateral Sclerosis (PLS)
 UMN affected
 Progressive Muscular Atrophy (PMA)
 LMN affected
- Diagnosis
o UMN (upper motor neurons) signs
 Babinski sign – upward response of big toe when stimulated
 Hyperreflexia – hyperactive repeating reflexes
 Spasticity
o LMN
 Muscle atrophy and weakness
 Fasciculations (looks like spasms but it is constant)
 Decreased muscle tone
 Hyporeflexia
o Difficulty diagnosing ALS as there could be both hyperreflexia (UMN) and
hyporeflexia (LMN) – symptoms may mask each other

Amyotrophic Lateral Sclerosis (ALS) – AKA Lou Gehring’s disease or Charcot’s disease
- Amyotrophy => neurogenic atrophy of the muscle
- Lateral sclerosis => hardness of the spinal cord seen when ALS patients are examined at
autopsy
o Caused by the proliferation of astrocytes and scars
- Forms of ALS:
o Classical sporadic
o Familial
o Geographic variant
- Age onset 55-65
o Can start at 45
- Seen in 1-2/100,000 – affecting more males
- 50% patients die within 3 years of onset, 90% die within 5 years
- Usually starts in the limbs, can be very heterogenous
o Can start in face too
- 30% bulbar (medulla oblongata) onset => tongue affected first
o Patients have issues with speech and swallowing
- All muscles are affected in ALS except ocular and bladder
- Respiratory problems are the major discomfort and major cause of death
- Interventions:
o No treatment
o End stage: Breathing tube or non-invasive mechanical ventilation (not easily
accessible since patients are often not mobile)

, PHAR 562


o Pharmacological treatment Riluzole
 Increased life expectancy by a few months

Suggested Disease Mechanism 1: Dying forward hypothesis
Cortical dysfunction and hyperexcitability
- Trans-synaptic glutamatergic excitotoxicity
o Something happens in the cortex triggers the hyperexcitability of motor neurons
leading to increased glutamate in the synaptic cleft leading to toxicity of lower
motor neurons (Dying forward hypothesis)
o Glutamate in the synaptic cleft is normally cleared by pre- and post-synaptic
terminals & by astrocytes that express EAAT2 (Excitatory amino acid transporter 2)
on the surface
 EAAT2
 Glutamate transporter on astrocytes that clear away glutamate
from synaptic cleft
 Decreased in ALS
- Hyperexcitability via NDMAR and AMPAR
o GluR2 deficiency occurs in some ALS patients
 It is required for Ca2+ entry into the cell
o Swelling of motor neurons observed due to an increased Na+ and Cl-, leading to
accumulation of water
- Riluzole
o Reduces cortical hyperexcitability and blocks glutamatergic neurotransmission
through 7 different mechanisms
 Glutamate release from presynaptic terminal inhibited by blocking Na+
and Ca2+ channels (1-2)
 Blocks NMDAR, AMPAR, and Kainate receptors in the postsynaptic
terminal, so that there is less Ca2+ influx (3,4,5)
 Potentiates glutamate uptake by astrocytes via EAAT2 (6)
 Inhibits glutamate release (7)
o Mechanism indicates dying forward mechanism is involved in ALS
 Heterogenous presentation of disease indicates that other mechanisms
may be involved too
- Pharmacology of Riluzole
o ADME
 Absorption: 50mg BID; Bioavailability: 60% oral
 Distribution: 96% bound to plasma protein (increasing its half-life)
 Metabolism: CYP1A2 hydroxylation
 Drug-drug interaction with other CYP1A2 substrates (e.g.,
acetaminophen, caffeine, warfarin)
 Excretion: 95% renal as glucoronides
o Adverse events: Blurred vision, difficulty breathing, weakness, dizziness, GI
discomfort

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller miryam_guirguis. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $10.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

76449 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$10.49
  • (0)
  Add to cart